Clinical Case Report

Cholestasis caused by panhypopituitarianism and acquired cytomegalovirus infection in a 2-month-old male infant
A case report

U Chan, MDa, Wai-Tao Chan, MDa,b,∗, Wei-Hsin Ting, MDc, Che-Sheng Ho, MDb, Hsi-Che Liu, MDc,f, Hung-Chang Lee, MDa

Abstract

**Rationale:** Septo-optic dysplasia (SOD) is a rare congenital disorder that may cause jaundice in infants. However, it is usually prone to neglect and misdiagnosis in infants with cholestasis because endocrine disorder such as panhypopituitarianism is rare in the cause of infantile cholestasis. We report a case of SOD concurrent with acquired cytomegalovirus (CMV) infection, who presented with prolonged jaundice as the first clinical sign.

**Patient concerns:** The patient was a 2-month-old male infant who presented with cholestasis, combined with fever and panhypopituitarianism.

**Diagnoses:** He was diagnosed with SOD and acquired CMV infection.

**Interventions:** He was treated with hormone replacement therapy and ganciclovir.

**Outcomes:** After correction of the pituitary hormone deficiency and ganciclovir treatment, significant improvements of cholestasis, retinal lesions, and growth rate were seen in our patient.

**Lessons:** Although an endocrine disorder such as panhypopituitarianism is rare in the cause of neonatal or infantile cholestasis, we must keep this reason in mind.

**Abbreviations:** CMV = cytomegalovirus, DBS = dried blood spots, MRI = magnetic resonance imaging, PCR = polymerase chain reaction, SOD = septo-optic dysplasia.

**Keywords:** cholestasis, cytomegalovirus, panhypopituitarianism, septo-optic dysplasia

1. Introduction

Septo-optic dysplasia (SOD) is a rare congenital disorder affecting 1 in 10,000 live births. It is characterized by the presence of 2 or more of the following: optic nerve hypoplasia, hypothalamic–pituitary dysfunction, and midline brain abnormalities. Panhypopituitarianism, a consequence of SOD, may cause cholestasis in neonates and infants. Neonatal or infantile cholestasis due to endocrine disorders is infrequent and poorly recognized. We report a case of SOD concurrent with acquired cytomegalovirus (CMV) infection, who presented with prolonged jaundice as the first clinical sign.

2. Case report

A 2-month-old formula-fed male Taiwanese infant was referred to our emergency department from a regional hospital with the chief complaint of prolonged jaundice and fever for 4 days. He was born to a 27-year-old, G1P1 mother at 41 weeks of gestational age, by vaginal delivery with a birth weight of 3.4 kg (25–50th birth weight percentile). His prenatal and perinatal history was uneventful, and the result of newborn screen was normal. His father has thalassemia. He had history of neonatal jaundice, neonatal hypoglycemia, and urinary tract infection with *Escherichia coli* at 5 days of age and had been successfully treated by a regional hospital.

He came to our emergency department when he was 2 months old, presented with icteric looking, fever, and decreased activity and appetite. Physical examination showed icteric skin and sclera, hepatomegaly (4 cm below the right costal margin), and splenomegaly (3 cm below the left costal margin), but no obvious facial dysmorphism or microgenesis. His weight and height were at the third to 15th percentile for chronological age. Initial laboratory data revealed microcytic anemia (hemoglobin, 7.3...
g/dL; mean cell volume, 67 fL; hematocrit, 22%). The blood biochemistry results were as follows: total bilirubin, 8.4 mg/dL (normal <1.2 mg/dL); direct bilirubin, 4 mg/dL (normal <0.5 mg/dL); aspartate aminotransferase, 30 U/L (normal 8–34 U/L); alanine aminotransferase, 67 U/L (normal 23–68 U/L); and γ-glutamyl transpeptidase, 192 IU/L (normal 7–80 IU/L). The blood glucose levels were in the normal range. Besides, several episodes of clay-colored stools were found after admission. Series workup for cholestatic jaundice including blood and urinary culture showed no bacterial growth. Abdominal sonography, magnetic resonance cholangiopancreatography, and cholescintigraphy showed normal liver and gallbladder anatomy and patent hepatic biliary tract, all of which excluded the possibility of biliary atresia.

Later, serologic test for CMV revealed elevated CMV immunoglobulin M (Ig M) and immunoglobulin G (Ig G) (IgM, 5.450 cutoff index; IgG, 23.17 IU/mL). Urine and blood polymerase chain reaction (PCR) for CMV were also positive (urine and blood PCR for CMV was 290 and 622 copies/mL, respectively). Active CMV infection was suspected, and we arranged further ophthalmological examination and brain sonography to evaluate CMV-associated complications. Ophthalmological examination showed bilateral CMV retinitis. Brain sonography demonstrated lobar type of holoprosencephaly (Fig. 1). Brain magnetic resonance imaging (MRI) showed agenesis of genu and rostrum of the corpus callosum, and ectopic posterior lobe of the pituitary gland in the hypothalamus (Fig. 2).

Based on the MRI findings, lobar holoprosencephaly and SOD were diagnosed. Visual-evoked potential study suggested bilateral visual–cortical pathway dysfunction. Pituitary hormone studies revealed secondary adrenal insufficiency, cortisol <1 ug/dL (normal 4.75–23.27 μg/dL); adrenocorticotropic hormone, 32.96 pg/mL (normal 10–70 pg/mL); secondary hypothyroidism, free T4, 0.87 ng/dL (normal 0.89–1.79 ng/dL), thyroid-stimulating hormone, 4.67 μU/mL (normal 0.25–4.00 μU/mL), and growth hormone deficiency, insulin-like growth factor-1, 13.5 ng/mL (normal 50–143 ng/mL). These lab data findings were consistent with panhypopituitarism. Genetic testing for HESX1 gene detected no pathologic sequence variants. In order to identify whether the CMV infection was congenital or acquired infection, we used the newborn screening sample of dried blood spots (DBS) on filter paper (Guthrie card) collected at birth for demonstration of CMV deoxyribonucleic acid (DNA) by PCR. However, CMV on DBS was negative.

The patient was started on hormone replacement with cortisone acetate (20 mg/m²/d) and levothyroxine (10 μg/kg/d). Because of the presence of systemic CMV infection complicated with CMV retinitis in the patient, intravenous ganciclovir (5 mg/kg/dose every 12 hours) was also administered. Significant improvement of cholestasis was seen in our patient after ganciclovir treatment and hormone replacement therapy. His jaundice subsided, and his stool became fully pigmented. Since CMV DNA was negative after 2 weeks of intravenous ganciclovir treatment, we changed the therapeutic strategy to valganciclovir tablets (16 mg/kg/dose every 12 hours). After 14 weeks of continuous valganciclovir therapy, total resolution of retinal lesions was noted on ophthalmological examination, and we discontinued valganciclovir. He remained clinically stable, and he was discharged from the hospital at the age of 3 months.

Outpatient department follow-up at 7 months of age showed that he was growing well, and his growth parameters were at the 25th to 50th percentile for weight and 75th to 85th percentile for height. Repeated tests of CMV DNA remained negative. He is currently receiving cortisone and thyroxine supplement at outpatient department without any side effects. A lifelong hormone replacement treatment with monitoring of serum hormone levels and symptoms of hormone deficiency are needed for this patient.

3. Discussion

We report a case of cholestatic jaundice caused by panhypopituitarism and acquired CMV infection in a 2-month-old male infant. Cholestasis in infants due to acquired CMV infection[1–4] had been reported widely in the previous literature. However, panhypopituitarism, a consequence of SOD, is a rare cause of cholestasis in infants. In addition, it is usually prone to neglect and misdiagnosis in infant with cholestasis. This case emphasizes the importance of endocrine disorders as one of the etiologies of prolonged jaundice in infants.

Cholestatic hyperbilirubinemia is defined as serum conjugated bilirubin greater than 1.0 mg/dL (if the total bilirubin is <5.0 mg/dL) or greater than 20% of the total serum bilirubin (if the total serum bilirubin is >5.0 mg/dL).[5] The most common causes of infantile cholestasis are biliary atresia (25.89%) and idiopathic neonatal hepatitis (26%). CMV is the most common infection identified (31.51%). However, endocrine disorders such as hypopituitarism or hypothyroidism are rare (2%) in the causes of infantile cholestasis.[6] The overall mortality rate of neonatal cholestasis is 25%, and biliary atresia is the most common underlying cause of mortality (67.6%).[7] The mechanisms of the development of cholestasis in pituitary hormone insufficiency/deficiency are unclear, but it is known that thyroid hormone, growth hormone, and cortisol are involved in the mechanisms.

Figure 1. (A and B) Sagittal and coronal section of brain sonography showed agenesis of genu and rostrum of the corpus callosum (arrowhead) and absence of septum pellucidum (arrow).
All 3 hormones are important independently in bile acid formation and excretion. Thyroid hormone and cortisol can influence the bile acid-independent bile flow and bile formation. Growth hormone can also modulate the biosynthesis and secretion of bile acids. Deficiency of growth hormone may affect liver function through decreased bile acid synthesis and structural abnormalities of the bile acid canaliculi. The infants with hypopituitarism usually present with elevation of both direct and total bilirubin.[5,8]

Hypopituitarism in patients with SOD is usually permanent and requires lifelong treatment. Growth hormone deficiency is the most common endocrine abnormality of SOD, followed by deficiencies of TSH and ACTH.[17] Other associated features include developmental delay, hypoglycemia, seizures, and visual impairment.[12]

Otherwise, CMV infection was another cause of cholestasis in our case. It was lack of powerful evidence to prove whether his CMV infection was congenital or acquired infection, although the latter was more preferred based on his clinical presentations. For this, we used DBS test to confirm it. DBS is effective to identify CMV infection: recent advances. Curr Opin Pediatr 2006;18:48–52.

In conclusion, the causes of infantile cholestasis are varied and complex. Some of the causes can result in substantial morbidity or mortality if treatment is delayed. Early detection of cholestatic jaundice and accurate diagnosis are important for successful treatment and an optimal prognosis. Although an endocrine disorder such as panhypopituitarism is rare in the causes of infantile cholestasis, we must keep this reason in mind. The early diagnosis and treatment of aggravated endocrine and neurologic functions may consequently reduce morbidity and mortality. We believe this case can remind clinicians the importance of evaluating pituitary and neurologic function in infantile cholestasis if the patient also has any specific phenotype consistent with hypopituitarism.

References
[1] Lanzieri TM, Dollard SC, Josephson CD, et al. Breast milk-acquired cytomegalovirus infection and disease in VLBW and premature infants. Pediatrics 2013;131:e1937–45.
[2] Schleiss MR. Role of breast milk in acquisition of cytomegalovirus infection: recent advances. Curr Opin Pediatr 2006;18:48–52.
[3] Nijman J, de Vries LS, Koopman-Esseboom C, et al. Postnatally acquired cytomegalovirus infection in preterm infants: a prospective study on risk factors and cranial ultrasound findings. Arch Dis Child Fetal Neonatal Ed 2012;97:F259–263.
[4] Hasosah MY, Kutbi SY, Al-Amri AW, et al. Perinatal cytomegalovirus hepatitis in Saudi infants: a case series. Saudi J Gastroenterol 2012;18:208–13.
[5] Fawaz R, Baumann U, Ekonk U, et al. Guideline for the Evaluation of Cholestatic Jaundice in Infants; joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2017;64:154–68.
[6] Gottesman LE, Del Vecchio MT, Aromoff SC. Etiologies of conjugated hyperbilirubinemia in infancy: a systematic review of 1692 subjects. BMC Pediatr 2015;15:192.
[7] Lee WS, Chai PF, Boey CM, et al. Aetiology and outcome of neonatal cholestasis in Malaysia. Singapore Med J 2010;51:434–9.
Ellaway CJ, Silink M, Cowell CT, et al. Cholestatic jaundice and congenital hypopituitarism. J Paediatr Child Health 1995;31:51–3.

Karnsakul W, Sawathiparnsch P, Nimkarn S, et al. Anterior pituitary hormone effects on hepatic functions in infants with congenital hypopituitarism. Ann Hepatol 2007;6:97–103.

Braslavsky D, Keselman A, Galoppo M, et al. Neonatal cholestasis in congenital pituitary hormone deficiency and isolated hypocortisolism: characterization of liver dysfunction and follow-up. Arq Bras Endocrinol Metabol 2011;55:622–7.

DeSalvo D, Pohl JF, Wilson DP, et al. Cholestasis secondary to panhypopituitarism in an infant. J Natl Med Assoc 2008;100:342–4.

Webb EA, Dattani MT. Septo-optic dysplasia. Eur J Hum Genet 2010;18:391–7.

Atapattu N, Ainsworth J, Willshaw H, et al. Septo-optic dysplasia: antenatal risk factors and clinical features in a regional study. Horm Res Paediatr 2012;78:81–7.

Kelberman D, Dattani MT. Septo-optic dysplasia—novel insights into the aetiology. Horm Res 2008;69:257–65.

Ferran K, Paiva IA, Gilban DL, et al. Septo-optic dysplasia. Arq Neuropsiquiatr 2010;68:400–5.